Immuneering earnings were -$54.4M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest IMRX earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$13.5M, up 16.2% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, IMRX reported annual earnings of -$56.0M, with -8.2% growth. The next IMRX earnings date is Aug 12, 2026.
On IMRX's earnings call on May 12, 2026, Immuneering (NASDAQ: IMRX) reported Q1 2026 earnings per share (EPS) of -$0.21, up 50% year over year. Total IMRX earnings for the quarter were -$13.46 million. In the same quarter last year, Immuneering's earnings per share (EPS) was -$0.42.
The next IMRX earnings date is Aug 12, 2026. Add IMRX to your watchlist to be reminded of Immuneering's next earnings date.
Is Immuneering profitable or losing money?
As of the last Immuneering earnings report, Immuneering is currently losing money. Immuneering's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$54.44 million, a 11.87% decrease year over year.
What was IMRX's earnings growth in the past year?
As of Immuneering's earnings date in May 12, 2026, Immuneering's earnings has grown year over year. IMRX earnings in the past year totalled -$54.44 million.
What are Immuneering's earnings expectations?
The current EPS estimate for Immuneering's earnings report in Aug 12, 2026 is -$0.25.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.